Our 2024 Sponsors

A big thank you to our sponsors. 


embecta, formerly part of BD, is one of the largest pure-play diabetes management companies in the world. We build on our nearly 100-year legacy in insulin delivery to empower people with diabetes to live their best life.  Through innovative solutions, partnerships and the passion of almost 2,000 employees around the globe, we live by a single purpose – Advance Every Day Together. We partner with the entire community of care to unite expertise, passion, and the pursuit of innovation that positively impacts people living with diabetes. Our vision is that one day we have a world where life is unlimited by diabetes. 


“GlucoRx, founded in 2011, is one of the UK’s leading suppliers committed to delivering high-quality, affordable, innovative medical products and platforms to improve the wellbeing of all people with diabetes. Keeping patients and clinicians at the centre of our ethos, we are dedicated to ensuring that everyone has access to the best integrated technology, using intuitive platforms to deliver optimum care”.


mylife Diabetescare offers a comprehensive portfolio of products and services for easy, discreet, and reliable self-treatment for people with diabetes.

Discover the range of products here including the mylife Loop, the adaptive automated insulin delivery system which learns and adjusts according to your needs, managed directly from your smartphone.

We are an innovative global healthcare company, driven by one purpose: we chase the miracles of science to improve people’s lives. Our team, across some 100 countries, is dedicated to transforming the practice of medicine by working to turn the impossible into the possible. We provide potentially life-changing treatment options and potentially life-saving vaccine protection to millions of people globally, while putting sustainability and social responsibility at the centre of our ambitions.

For more information visit: www.sanofi.co.uk or www.sanofi.ie


Insulin Safety Week 2024 has been funded by Embecta, GlucoRx, Medtronic, Sanofi and Ypsomed which have had no input into any arrangements or content.